2021-09-06 Ruilian Xincai (688550) issued a notice saying: the majority of investors investigated our company on 2021-09-01, and the survey was received by Liu Xiaochun, chairman and secretary of the board of directors (temporary acting), general manager Liu Jiefeng, and financial director Wang Yinbin.

The main contents of this survey are as follows:
First, the main content of the opening speech; answer solicitation questions; investors online text interaction.
Second, answer the question of solicitation.
1: what is intermediate B, please? could you be more specific? What kind of drugs do you use? Large molecules or small molecules? Answer: the pharmaceutical intermediate B mentioned in the semiannual report belongs to the field of small molecule CDMO and is used in the new dosage form of alatinib. problem
2: there is no general reason for the order of a pharmaceutical intermediate supplied to AstraZeneca PLC's lung cancer drug. A: the pharmaceutical intermediate you are concerned about is selling well in 2021, and there is no no order. problem
3:PA0045, Elotenilo patent, patent period until December 11, 2021, which is the first imitation in China? Is it still supplied by Credit Suisse? Is the first imitation in China Ausaikang? A: as far as we know, the expiration date of Elotenilo's patent is 2035. At present, there is no generic drug or generic manufacturer of this drug in China.
III. The problem of online text interaction among investors
1: your company's stock price has been broken since it was listed on the stock market. What do you think of it? What measures should the company take in terms of market capitalization management? A: dear investors, how do you do? In the short term, the stock price in the secondary market is affected by many factors. in the long run, the company's stock price should match the company's operating performance and intrinsic value, so the company will continue to strengthen operation and management, expand various businesses, and maintain healthy growth in performance. continue to consolidate intrinsic value, while maintaining good interaction with investors to create returns for shareholders. We believe that with the continuous growth of the company's performance, the company's stock price will certainly reflect the real value of the company. Thank you for your attention! problem
2: introduce the progress of demolition in Weinan area. Is there a deadline? A: dear investors, how do you do? The company has disclosed in the semi-annual report that all the villagers within the safety distance around Ruilian Pharmaceutical have signed the relocation agreement, and so far, the houses of more than 30 villagers have been demolished, and other houses to be demolished are being demolished in an orderly manner. it has no impact on the overall progress of the API project, and the construction of the API project is advancing normally as planned. Thank you for your attention! problem
3:PA0045, Elotenilo patent, patent period until December 11, 2021, which is the first imitation in China? Is it still supplied by Credit Suisse? Is the first imitation in China Ausaikang? A: dear investors, how do you do? As far as we know, the patent of Erotiniros expires in 2035. At present, there are no generic drugs and generic manufacturers of this drug in China. Thank you for your attention! problem
4: we see that the company's pharmaceutical business in the first half of the year is not as expected. What is the annual revenue forecast of Pharmaceutical CDMO this year? A: dear investors, how do you do? Judging from the current order situation, the annual revenue of Pharmaceutical CDMO in 2021 is expected to maintain a certain degree of growth. Thank you for your attention!

Main business: research, development, production and marketing of liquid crystal display materials, organic electroluminescent display materials, pharmaceutical intermediates (excluding drugs), pesticide intermediates and other fine chemicals (excluding hazardous, monitoring and precursor chemicals); chemical processing (excluding hazardous, monitoring and precursor chemicals); chemical mechanical processing, equipment installation Sales of chemical reagents and chemical raw materials (excluding hazardous, monitoring and precursor chemicals); chemical technical consultation, technical services (excluding flammable and explosive dangerous goods above), production and sales of optoelectronic raw materials, electronic components and mechanical and electrical products. (the above business scope except for the special control and pre-license projects stipulated by the state) (the projects that must be approved according to law can only be carried out with the approval of the relevant departments)

According to the 2021 report of Ruilian Xincai, the company's main income was 687 million yuan, up 45.16% from the same period last year; the net profit from its parent was 101 million yuan, up 23.06% from the same period last year; deducting 89.3912 million yuan from non-net profit, up 9.78% from the same period last year; debt ratio 14.94%, investment income 3.9705 million yuan, financial expenses-6.9697 million yuan, gross profit margin 35.04%.